BioTime (NYSEAMERICAN:BTX) had its price objective cut by Raymond James from $6.00 to $5.00 in a report published on Monday. They currently have an outperform rating on the biotechnology company’s stock.

A number of other equities analysts have also commented on the company. HC Wainwright started coverage on BioTime in a research note on Thursday, February 21st. They issued a buy rating and a $4.00 price objective on the stock. Dawson James began coverage on BioTime in a research note on Thursday, February 7th. They set a buy rating on the stock. Oppenheimer began coverage on BioTime in a research note on Tuesday, December 11th. They set an outperform rating and a $3.50 price target on the stock. Maxim Group reaffirmed a buy rating and set a $3.00 price target on shares of BioTime in a research note on Wednesday, January 30th. Finally, CIBC began coverage on BioTime in a research note on Tuesday, December 11th. They set an outperform rating and a $3.50 price target on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and an average target price of $3.46.

Shares of BTX stock opened at $1.64 on Monday. BioTime has a one year low of $0.66 and a one year high of $2.81.

BioTime (NYSEAMERICAN:BTX) last posted its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.74 million.

Several institutional investors and hedge funds have recently modified their holdings of BTX. Defender Capital LLC. acquired a new position in shares of BioTime during the fourth quarter valued at $3,629,000. Two Sigma Investments LP lifted its stake in shares of BioTime by 265.9% during the fourth quarter. Two Sigma Investments LP now owns 529,977 shares of the biotechnology company’s stock valued at $484,000 after acquiring an additional 385,116 shares during the period. BlackRock Inc. lifted its stake in shares of BioTime by 3.1% during the third quarter. BlackRock Inc. now owns 6,102,467 shares of the biotechnology company’s stock valued at $14,340,000 after acquiring an additional 185,826 shares during the period. Bridgeway Capital Management Inc. lifted its stake in shares of BioTime by 1,066.5% during the third quarter. Bridgeway Capital Management Inc. now owns 190,700 shares of the biotechnology company’s stock valued at $448,000 after acquiring an additional 174,352 shares during the period. Finally, Jefferies Group LLC lifted its stake in shares of BioTime by 273.0% during the third quarter. Jefferies Group LLC now owns 117,571 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 86,049 shares during the period.

BioTime Company Profile

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Further Reading: How are institutional investors different from individual investors?

Analyst Recommendations for BioTime (NYSEAMERICAN:BTX)

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.